MobiHealth News April 4, 2024

FDA clearance opens US door for European RPM system

Current solutions for remote health monitoring can be seen as invasive by patients and mostly do single variant intermittent tracking. FDA clearance brings one of Europe’s most advanced real-time continuous remote monitoring systems to the US market for the first time.

A patient-friendly multi-sensor bracelet which helps to address some of the key challenges around the adoption of remote patient monitoring systems (RPM) has been given clearance by the United States Food and Drug Administration (FDA).

Corsano Health’s CardioWatch System is an advanced real-time monitoring system, which consists of a bracelet worn by an adult patient (at least 22 years old), a web-based browser, and a mobile app that can operate...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Digital Health, FDA, Govt Agencies, Patient / Consumer, Provider, Technology
Related Articles:
FDA warns GLP-1 compounder over safety rules
GLP-1 drug approvals: A breakdown
Rethinking FDA’s Accelerated Approval Pathway: New Draft Guidances and Implications for Drug Companies
FDA approves Novo Nordisk's Ozempic to treat chronic kidney disease in those with diabetes, expanding its use
Certainty vs. speed: How do patients feel about the tradeoff for new cancer drugs?

Share This Article